在怀疑冠状动脉疾病的患者中评估非侵入性的β-阻塞剂和结果
Yu Kang1, Zhuoran Zhao1, Zixuan Yang1
1Department of Cardiology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
The American journal of medicine
|May 9, 2025
概括
贝塔抑制剂的使用没有影响以前没有心脏病发作或心力衰竭的慢性冠状动脉疾病患者的临床结果. 这一发现适用于通过非侵入性测试诊断的个体,这表明在这个特定的患者群体中没有显著的益处.
科学领域:
- 心脏病学 心脏病学
- 临床医学 临床医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 慢性冠状动脉疾病 (CAD) 的管理通常涉及β阻塞剂.
- 在没有急性事件或心力衰竭的情况下,β阻塞剂在稳定的CAD中的作用需要进一步澄清.
研究的目的:
- 评估β-阻断剂使用与慢性CAD患者的临床结果之间的关联.
- 为了确定β抑制剂是否会影响通过非侵入性检测诊断的患者的结果,但不包括心肌梗塞或心力衰竭患者.
主要方法:
- 从前性多中心成像研究评估胸痛 (PROMISE) 试验的数据进行了后期分析.
- 包括8250名患有低至中等CAD风险的患者,不包括以前心肌梗塞或心力衰竭的患者.
- 基于基线β-阻断剂使用的复合结局 (因任何原因死亡,心肌梗塞,不稳定性胸痛住院治疗) 的分析.
主要成果:
- 在具有负 (23.9%) 和正 (28.6%) 非侵入性测试结果的患者中,β-阻断剂的使用类似.
- 在任何一个队列中,beta阻断剂使用者和非使用者之间没有观察到主要复合结果的显著差异.
- 针对主要结果的调整后危险比为1.106 (P=.586) 在消极队列和1.077 (P=.759) 在积极队列.
结论:
- 贝塔阻断剂治疗没有证明对慢性CAD患者的临床结果有显著影响.
- 这一发现特别适用于使用非侵入性检测诊断的患者,而没有心肌梗塞或心力衰竭病史.
- 这项研究表明,β-阻断剂可能对治疗慢性CAD患者的这一特定亚组来说并不必不可少.
更多相关视频
05:41Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control
Published on: December 16, 2022
3.2K
10:28Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
Published on: March 15, 2022
4.7K
相关概念视频
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
479
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
479
01:22Heart Failure Drugs: β-Blockers
273
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
273
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
384
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
384
01:28Antihypertensive Drugs: Types of β-Blockers
513
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
513
01:25Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers
453
β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but...
453
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
648
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
648